Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on the diagnosis and treatment of pancreatic cystic lesions
The event was co-sponsored by several leading players in the Medtech and Pharma industries, confirming its status as a major event at DDW
Paris and Boston, May 6, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced completion of the largest annual pancreatic cyst consortium held at the Digestive Disease Week® (DDW) Conference in San Diego, California, on Monday May 5, 2025. The detailed program is available on the Mauna Kea Technologies website at the following link:
https://www.landing.maunakeatech.com/hubfs/ddw/DDW_2025_Consortium_Agenda.pdf
The consortium brought together more than 75 physicians from across the United States with a focus on cutting-edge advancements in the diagnosis, classification, risk stratification, and treatment of pancreatic cystic lesions and pancreatic cancer. Attendance tripled compared to the 2024 meeting, reflecting the growing interest among the medical community in this field. Central to the discussions was the growing impact of endoscopic ultrasound with Cellvizio needle-based Confocal Laser Endomicroscopy (EUS-nCLE) in enabling earlier and more accurate diagnoses and clinical decisions before any therapy begins, with the goal of increasing non-surgical treatment options.
The consortium was led by Dr. Somashekar (Som) Krishna, MD, MPH, Professor of Medicine and Director of Advanced Endoscopy at The Ohio State University Wexner Medical Center and principal investigator of the CLIMB1 study. It was co-sponsored by 9 leading medical device and pharmaceutical products companies, demonstrating strong cross-industry commitment to advancing care for the millions of patients affected by pancreatic cystic lesions worldwide.
“This year’s consortium marks a turning point in how the medical community and the industry approach pancreatic cyst management and treatment,” said Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies. “Bringing together more than 75 top physicians and 9 committed industry partners shows that the ecosystem around EUS-nCLE, RFA2, and AI is maturing rapidly – and with it, our ability to change the standard of care for patients facing pancreatic lesions. A clear momentum is building around this application, driven by the recent endorsement of nCLE in European clinical guidelines and the surge of interest we’re now seeing in the United States at DDW. We’re proud to help lead this transformation and deeply grateful to our collaborators and clinical pioneers who are making it possible. With Cellvizio, we are targeting one of the largest unmet clinical issues in gastroenterology – and changing the trajectory for many patients at risk of pancreatic cancer.”
[1] ClinicalTrials.gov: NCT03492151
[2] Radiofrequency Ablation
